Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | CALML3 | P27482 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SDHA | P31040 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393444 | 0.91 | MAOA (0.53) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL4811525 | 0.88 | MAOA (0.50) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1393207 | 0.87 | MAOA (0.49) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL14432507 | 0.86 | MAOA (0.59) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1394410 | 0.86 | MAOA (0.48) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1394413 | 0.86 | MAOA (0.48) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL14432619 | 0.86 | MAOA (0.60) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL1395020 | 0.84 | MAOA (0.51) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL14432599 | 0.84 | MAOA (0.62) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL14432626 | 0.84 | MAOA (0.66) | MAOACALML3MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | MELINTA SUBSIDARY CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2492264-A2 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | Rib-X Pharmaceuticals, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-1656370-B1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB X PHARMACEUTICALS INC (US) | 2012-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471046-B2 | Method for treating, preventing, or reducing the risk of skin infection | CUTA, CYP17A1, HSD17B11 | MAOA 1569/4885CALML3 4401/4885MAOB 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.